Followers | 10 |
Posts | 605 |
Boards Moderated | 0 |
Alias Born | 06/30/2014 |
Sunday, October 21, 2018 3:25:10 PM
@ .72/
Reverse split and NASDAQ listing coming?
Most institutions can’t buy a B.B. stock under $5/ share
Director PK has all the phone numbers, won’t tout but may ‘inform’ his old colleagues
My Prediction: $15 ( pre reverse split) by mid year
$80 in two years, just like CC did with Questor, just quicker
Can’t copy link:
https://ih.advfn.com/p.php?pid=nmona&article=78494640
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 12, 2018
RELMADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Nevada 333-184881 45-5401931
(State or other jurisdiction
of incorporation) (Commission File Number) (IRS Employer
Identification No.)
750 Third Avenue, 9th Floor
New York, NY
10017
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (212) 547-9591
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4
Item 1.01 Entry into a Material Definitive Agreement.
On October 12 and 18, 2018, Relmada Therapeutics, Inc. (the “Company”) conducted closings (the “Closings”) of its private placement of securities (the “Offering”) pursuant to a Unit Purchase Agreement, dated as of October 12 and 18, 2018 (collectively, the “Purchase Agreements”) and Subscription Agreements, dated as of October 12 and 18, 2018 (collectively, the “Subscription Agreements”), with certain accredited investors named therein (the “Investors”) pursuant to which: the Investors at the Closings agreed to purchase (i) an aggregate of 3,644,440 shares ( the “Shares”) of common stock at $0.90 per share and (ii) five-year warrants to purchase an aggregate of 2,368,887 shares of common stock at an exercise price of $1.50 per share (the “Warrants”). The Company received $3,279,998 in gross proceeds from the sale of securities under the Purchase Agreement at the Closings.
As required by the Purchase Agreement, at the Closings, the investors also became parties to Registration Rights Agreements dated as of October 12 and 18, 2018 pursuant to which the Company will be required to register with the United States Securities and Exchange Commission such Shares and the shares of Common Stock underlying the Warrants (the “Warrant Shares”). If the registration statement is not filed or declared effective within the timeframe set forth in the Registration Rights Agreements, the Company is obligated to pay the investors an amount equal to 1% of the total purchase price of the securities per month (up to a maximum of 6% in the aggregate) until such failure is cured.
As a result of the Closings, $7,726,832 (which includes principal and interest) of Company’s outstanding 7% Convertible Promissory Notes issued in 2017 and 2018 automatically converted into 10,731,676 shares of our common stock, based on a conversion price of $0.72 per share.
Alexander Capital, LP (“Alexander Capital”), a FINRA registered broker dealer, acted as exclusive placement agent with respect to the Offering. In connection with the Closings, the placement agent received a cash fee of $280,000 and warrants to purchase 303,333 shares of common stock at an exercise price of $1.50 per share. The broker-dealer will also be paid a non-accountable 1% allowance (or $28,000) for expenses. Alexander Capital was also paid an upfront due diligence fee of $20,000.
Recent RLMD News
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm • PR Newswire (US) • 09/17/2024 01:36:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 09:47:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 09:46:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 09:46:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/30/2024 08:23:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:05:43 PM
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm • PR Newswire (US) • 07/25/2024 06:47:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:25:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:24:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:24:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:24:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:24:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:23:59 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:06:11 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 10:55:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:28:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:28:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:11:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:00:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:56 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM